Program
Ranolazine
Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.
Drug pageRanolazine: every studyMany companies study it; this page follows only the 25 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 180 open or running | phase 4since Mar 24, 2008 | Sep 8, 2004 | none ahead |
| Menarini Groupits history only | 20 open or running | phase 2since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Amit Malhotra, MDits history only | 10 open or running | phase 4since Jan 26, 2017 | Jan 26, 2017 | none ahead |
| Haisco Pharmaceutical Groupits history only | 10 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | none ahead |
| Novartisits history only | 10 open or running | phase 2since Mar 21, 2012 | Mar 21, 2012 | none ahead |
| OBS Pakistanits history only | 10 open or running | phase 4since Mar 15, 2018 | Mar 15, 2018 | none ahead |
| TSH Biopharmits history only | 10 open or running | no phasesince Jan 7, 2018 | Jan 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Sep 8, 2004.
- Nov 11, 2011Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01472185 · 465 enrolled · United States, Czech Republic, Hungary and more
- Dec 15, 2011Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01494987 · 431 enrolled · United States, Czech Republic, Hungary and more
- Jan 18, 2012Phase 2 study in Atrial FibrillationGilead Sciences · NCT01522651 · 134 enrolled · United States, Germany, Israel and more
- Feb 10, 2012Menarini Group’s first study: phase 2 study in Atrial FibrillationNew to Menarini GroupMenarini Group · NCT01534962 · 241 enrolled · Germany, Italy, Spain and more
- Feb 14, 20122 phase 1 studies in Diabetes Mellitus, Type 2Gilead Sciences · NCT01546597, NCT01546558
- Mar 13, 2012Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01555164 · 442 enrolled · United States, Canada, Czech Republic and more
- Mar 21, 2012Novartis’s first study: phase 2 study in Cardiovascular DiseasesNew to NovartisNovartis · NCT01562041 · 14 enrolled · United States
- Jul 26, 2012Phase 1 study in Renal InsufficiencyGilead Sciences · NCT01675973 · 4 enrolled · United States
- Apr 17, 2013Phase 1 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01843127 · 24 enrolled · United States
- Apr 29, 2016Phase 1 study in Healthy Male IndividualsMenarini Group · NCT02817932 · 120 enrolled · Korea, Republic of
- Jan 26, 2017Amit Malhotra, MD’s first study: phase 4 study in Angina PectorisNew to Amit Malhotra, MDAmit Malhotra, MD · NCT03044964 · 40 enrolled · United States
- Jan 7, 2018TSH Biopharm’s first study: no phase study in Angina PectorisNew to TSH BiopharmTSH Biopharm · NCT03401502 · 20 enrolled · Taiwan
- Mar 15, 2018OBS Pakistan’s first study: phase 4 study in Angina, StableNew to OBS PakistanOBS Pakistan · NCT03486561 · 2,000 enrolled
- Jun 27, 2025Haisco Pharmaceutical Group’s first study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07054255 · 72 enrolled · China
TargetBeta
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07054255Healthy · China | 1 | Completed | Haisco Pharmaceutical Group | Nov 9, 2020 | 72 |
| NCT03486561Angina, Stable | 4 | UNKNOWN | OBS Pakistan | Sep 30, 2018 | 2,000 |
| NCT03401502Angina Pectoris · Taiwan | – | Completed | TSH Biopharm | Mar 30, 2019 | 20 |
| NCT03044964Angina Pectoris · United States | 4 | UNKNOWN | Amit Malhotra, MD | Oct 2017 | 40 |
| NCT02817932Healthy Male Individuals · Korea, Republic of | 1 | UNKNOWN | Menarini Group | Jul 2016 | 120 |
| NCT01843127Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gilead Sciences | Sep 2013 | 24 |
| NCT01675973Renal Insufficiency · United States | 1 | Terminated | Gilead Sciences | Aug 2012 | 4 |
| NCT01562041Cardiovascular Diseases · United States | 2 | Terminated | Novartis | Jan 2, 2014 | 14 |
| NCT01555164Diabetes Mellitus, Type 2 · United States, Canada, Czech Republic and more | 3 | Completed | Gilead Sciences | Sep 2013 | 442 |
| NCT01546558Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gilead Sciences | Mar 2012 | 25 |
| NCT01546597Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gilead Sciences | Mar 2012 | 24 |
| NCT01534962Atrial Fibrillation · Germany, Italy, Spain and more | 2 | Completed | Menarini Group | Oct 2013 | 241 |
| NCT01522651Atrial Fibrillation · United States, Germany, Israel and more | 2 | Completed | Gilead Sciences | Mar 10, 2014 | 134 |
| NCT01494987Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more | 3 | Completed | Gilead Sciences | Aug 2013 | 431 |
| NCT01472185Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more | 3 | Completed | Gilead Sciences | Oct 2013 | 465 |
| NCT01442038Coronary Artery Disease · United States, Austria, Belgium and more | 3 | Completed | Gilead Sciences | Feb 2015 | 2,651 |
| NCT01425359Angina Pectoris · United States, Belarus, Bulgaria and more | 4 | Completed | Gilead Sciences | Oct 2012 | 949 |
| NCT01334203Angina Pectoris | 4 | Withdrawn | Gilead Sciences | Oct 2012 | 0 |
| NCT01221272Myocardial Ischemia · United States, Canada, Czech Republic and more | 4 | Completed | Gilead Sciences | Sep 2012 | 81 |
| NCT01163721Diabetes Mellitus, Type 2 · United States | 2 | Completed | Gilead Sciences | Nov 2010 | 80 |
| NCT01163734Heart Failure, Diastolic · Germany | 2 | Completed | Gilead Sciences | Feb 2011 | 20 |
| NCT00832572Coronary Artery Disease · United States | 4 | Terminated | Gilead Sciences | Jun 2009 | 5 |
| NCT00644332Chronic Angina · United States | 4 | Completed | Gilead Sciences | Jan 2011 | 172 |
| NCT00099788Myocardial Ischemia · United States | 3 | Completed | Gilead Sciences | Feb 2007 | 6,560 |
| NCT00091429Angina Pectoris | 3 | Completed | Gilead Sciences | Feb 2005 | 500 |
How it is read
Names in the registry
- “Ranolazine”, 24 entries
- “Test formulation (Ranolazine extended-release tablets)”, 1 entry
- “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
- “Ranolazine 500 mg”, 1 entry
- “Ranolazine plus Metoprolol Combination”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
- Angina Pectoris, 5 studies
- Atrial Fibrillation, 3 studies
- Coronary Artery Disease, 2 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.